I. Updates on 2025-2026 Northern Hemisphere Influenza Vaccine Strains

一、2025-2026年北半球流感疫苗毒株更新

To maintain vaccine efficacy, WHO regularly updates influenza vaccine strains based on global epidemiological, virological, and serological analyses. On February 28, 2025, WHO announced the recommended strains for the 2025-2026 northern hemisphere influenza season1:

为保证疫苗效力，WHO会根据全球流行病学、病毒学和血清学分析，定期更新流感疫苗株。2025年2月28日，WHO公布了2025-2026年北半球流感季节推荐的疫苗株1：

1. Trivalent egg-based vaccines

1. 三价基于鸡蛋的疫苗

2. Trivalent cell culture- or recombinant protein-based vaccines

2. 三价细胞培养或重组蛋白疫苗

3. Quadrivalent egg- or cell culture/recombinant-based vaccines (unchanged from 2024)

3. 四价鸡蛋或细胞培养/重组疫苗（与2024年相同）

II. Comparison of 2024-2025 vs. 2025-2026 Vaccine Components

二、2024-2025与2025-2026疫苗成分的比较

Table 1.

表1。

Key updates of influenza vaccine composition for the 2025–2026 northern hemisphere influenza season.

2025-2026年北半球流感季节流感疫苗成分的主要更新。

1. H3N2 Strain Substitution

1. H3N2毒株替换

2. No Changes to H1N1 or B/Victoria Lineage

2. H1N1或B/Victoria谱系没有变化

3. Summary

3. 总结

III. Recombinant Antigens: Critical Materials for Vaccine Research

III. 重组抗原：疫苗研究的关键材料

Table 2

表 2

. Key target antigens (HA, NA, NP) play vital roles in influenza vaccine, drug, and diagnostic development

关键靶抗原（HA、NA、NP）在流感疫苗、药物和诊断开发中发挥着至关重要的作用。

Applications of Recombinant Antigens:

重组抗原的应用：

Figure 1. Recombinant HA protein used to measure serum antibody levels in vaccinated mice 2.

图1. 用于测量接种疫苗小鼠血清抗体水平的重组HA蛋白。

IV. Sino Biological Unveils Comprehensive Influenza Research Reagents for 2025-2026 Vaccine Strains

IV. 义翘神州推出针对2025-2026疫苗株的全面流感研究试剂

Sino Biological, a leading provider of biological reagents and services, has announced the release of its latest portfolio of influenza research reagents. Designed to support the development of vaccines for the 2025-2026 northern hemisphere influenza season, the new offerings include high-quality recombinant HA, NA, and NP proteins.

义翘神州，作为生物试剂和服务的领先供应商，宣布推出其最新的流感研究试剂组合。新推出的产品旨在支持2025-2026年北半球流感季节疫苗的开发，包括高质量的重组HA、NA和NP蛋白。

These reagents are now available for immediate order, providing researchers with the tools they need to accelerate their studies and contribute to global influenza prevention efforts. For more details, please visit our website: www.sinobiological.com.

这些试剂现在可以立即订购，为研究人员提供加速研究所需的工具，并为全球流感预防工作做出贡献。欲了解更多信息，请访问我们的网站：www.sinobiological.com。

Reference:

参考：

1.    Recommendations announced for influenza vaccine composition for the 2025–2026 northern hemisphere influenza season. https://www.who.int/news/item/28-02-2025-recommendations-announced-for-influenza-vaccine-composition-for-the-2025-2026-northern-hemisphere-influenza-season#:~:text=a%20B/Austria/1359417/,Victoria%20lineage)%2Dlike%20virus..

1.    公布了2025-2026年北半球流感季节流感疫苗组成的建议。https://www.who.int/news/item/28-02-2025-recommendations-announced-for-influenza-vaccine-composition-for-the-2025-2026-northern-hemisphere-influenza-season#:~:text=a%20B/Austria/1359417/,Victoria%20lineage)%2Dlike%20virus..

2.    Andersen, T. K. et al. Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief. Front Immunol 12, (2021).

2.    Andersen, T. K. 等。针对流感的大流行预防：用于快速救济的DNA疫苗。《免疫学前沿》第12卷，（2021年）。